SG11201506509TA - Use of pidotimod to treat inflammatory bowel disease - Google Patents

Use of pidotimod to treat inflammatory bowel disease

Info

Publication number
SG11201506509TA
SG11201506509TA SG11201506509TA SG11201506509TA SG11201506509TA SG 11201506509T A SG11201506509T A SG 11201506509TA SG 11201506509T A SG11201506509T A SG 11201506509TA SG 11201506509T A SG11201506509T A SG 11201506509TA SG 11201506509T A SG11201506509T A SG 11201506509TA
Authority
SG
Singapore
Prior art keywords
pidotimod
inflammatory bowel
bowel disease
treat inflammatory
treat
Prior art date
Application number
SG11201506509TA
Other languages
English (en)
Inventor
Federico Mailland
Francesco Scarci
Maurizio Caserini
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of SG11201506509TA publication Critical patent/SG11201506509TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201506509TA 2013-04-05 2013-04-05 Use of pidotimod to treat inflammatory bowel disease SG11201506509TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/057208 WO2014161595A1 (en) 2013-04-05 2013-04-05 Use of pidotimod to treat inflammatory bowel disease

Publications (1)

Publication Number Publication Date
SG11201506509TA true SG11201506509TA (en) 2015-10-29

Family

ID=48048059

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506509TA SG11201506509TA (en) 2013-04-05 2013-04-05 Use of pidotimod to treat inflammatory bowel disease

Country Status (18)

Country Link
US (1) US20160058739A1 (zh)
EP (1) EP2981289A1 (zh)
JP (1) JP6122208B2 (zh)
KR (1) KR20150144743A (zh)
CN (1) CN105209072A (zh)
AU (1) AU2013385170A1 (zh)
BR (1) BR112015025296A2 (zh)
CA (1) CA2901338A1 (zh)
EA (1) EA201591930A1 (zh)
HK (1) HK1216150A1 (zh)
MA (1) MA38455B1 (zh)
MX (1) MX2015014061A (zh)
NI (1) NI201500147A (zh)
PH (1) PH12015502305A1 (zh)
SG (1) SG11201506509TA (zh)
TN (1) TN2015000433A1 (zh)
UA (1) UA113467C2 (zh)
WO (1) WO2014161595A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
EP1673092B1 (en) * 2003-10-17 2007-08-15 4 Aza Ip Nv Heterocycle-substituted pteridine derivatives and their use in therapy
CN101134034A (zh) * 2006-08-29 2008-03-05 江卫世 免疫促进药及其制备方法
US20090142769A1 (en) * 2007-11-29 2009-06-04 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for determining anti-TNF therapeutic response
CN101623499A (zh) * 2008-07-07 2010-01-13 杨喜鸿 抗生素和匹多莫德的药物组合物及其制备方法和药物应用
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
CN102234313B (zh) * 2011-08-16 2013-02-27 青岛康地恩药业股份有限公司 一种匹多莫德的合成方法
CN102525903B (zh) * 2012-01-20 2014-07-30 江苏吴中医药集团有限公司 一种匹多莫德的口服液体制剂

Also Published As

Publication number Publication date
PH12015502305A1 (en) 2016-02-15
BR112015025296A2 (pt) 2017-07-18
JP6122208B2 (ja) 2017-04-26
KR20150144743A (ko) 2015-12-28
CA2901338A1 (en) 2014-10-09
MA38455B1 (fr) 2018-05-31
CN105209072A (zh) 2015-12-30
JP2016515591A (ja) 2016-05-30
AU2013385170A1 (en) 2015-09-24
MA38455A1 (fr) 2017-12-29
UA113467C2 (uk) 2017-01-25
WO2014161595A1 (en) 2014-10-09
HK1216150A1 (zh) 2016-10-21
NI201500147A (es) 2016-01-06
TN2015000433A1 (en) 2017-01-03
US20160058739A1 (en) 2016-03-03
EA201591930A1 (ru) 2016-02-29
MX2015014061A (es) 2016-04-07
EP2981289A1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
HK1220980A1 (zh) 用於治療龐貝氏症的方法和組合物
EP2971127A4 (en) DIAGNOSTIC AND TREATMENT METHODS FOR INFLAMMATORY INTESTINAL DISEASE
IL240509A0 (en) Fluorescence imaging of inflammatory diseases
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HUE064634T2 (hu) Kardiovaszkuláris betegségek kezelése
IL284969A (en) Diagnosis and treatment of autoimmune diseases
HK1221898A1 (zh) 腸易激綜合徵和炎性腸病的診斷和治療
ZA201408059B (en) Compositions and methods for the treatment of inflammatory bowel disease
IL244453A0 (en) Methods for determining response to medical treatment
HK1220896A1 (zh) 拮抗劑治療阿爾茲海默症的方法
HK1220127A1 (zh) 自身免疫性疾病的治療
HK1218249A1 (zh) 用於治療炎症性腸道疾病的化合物和方法
EP3046629A4 (en) Treatment of inflammatory skin disease
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
HRP20190315T1 (hr) Uporaba tiazolo pirimidinona radi liječenja upalnih bolesti crijeva
HK1222400A1 (zh) 抗嗜酸細胞活化趨化因數抗體在治療炎症性腸病中的應用
HK1216150A1 (zh) 匹多莫德治療炎症性腸病的用途
PL2801352T3 (pl) Ulegające rozpadowi w jamie ustnej formulacje lakozamidu
GB201309358D0 (en) Aiding assessment of prognosis in inflammatory disease
PT2870968T (pt) Tratamento de doenças inflamatórias do intestino com clinoptilolite
HK1216151A1 (zh) 匹多莫德治療腸易激綜合症的用途
GB201321628D0 (en) Treatment of disease
GB201306411D0 (en) Treatment of inflammatory conditions
GB201320014D0 (en) Treatment of cardiovascular disease
GEP201706683B (en) Usage of pidotimod to treat inflammatory bowel diseases